Alpha Cognition  has announced that the United States Patent and Trademark Office has granted US Patent No. 12,589,099, covering the use of ALPHA-1062 for the treatment of Traumatic Brain Injury. Issued on March 31, 2026, the patent includes claims for treating both confirmed and suspected cases of TBI using the company’s investigational therapy.

The newly granted patent strengthens Alpha Cognition’s intellectual property portfolio and complements existing protections for ALPHA-1062 and Zunveyl. With protection extending through 2045, the patent aligns with the company’s long-term strategy to maximise the value and lifecycle of its key assets.

“This patent marks an important milestone in expanding our platform beyond Alzheimer’s disease,” said Michael McFadden, chief executive officer of Alpha Cognition. He noted that traumatic brain injury represents a significant unmet medical need, with no approved therapies currently available, and highlighted a potential USD 14 billion market opportunity.

McFadden added that advancing ALPHA-1062 into TBI indications positions the company to address a large underserved patient population while enhancing the commercial potential of its broader pipeline.

Alpha Cognition, a commercial-stage biopharmaceutical company, focuses on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury. Its approved therapy, Zunveyl, is a next-generation acetylcholinesterase inhibitor designed to treat Alzheimer’s disease with potentially reduced gastrointestinal side effects.

ALPHA-1062 is also being explored in combination therapies, including with memantine for moderate to severe Alzheimer’s dementia, as well as in an intranasal formulation for cognitive impairment linked to mild TBI.

The patent milestone underscores Alpha Cognition’s efforts to expand its therapeutic reach into new neurological indications while reinforcing its commitment to innovation in areas with limited treatment options.